SolidIO funding news – Medtech Company Solid IO Secures €800k in Funding

This investment accelerates the development of Solid IO’s tumor-on-chip platform, a breakthrough technology that enables real-time, biologically relevant insights to guide personalized cancer treatment and immunotherapy advancements.

Ending the Guesswork in Cancer Care

It’s tumor-on-chip platform replicates the patient’s tumor microenvironment, generating high-accuracy, real-time data on how individual cancers respond to immunotherapies and combination treatments. By integrating bioengineering, organ-on-chip technology, the platform helps clinicians select the most effective therapy from day one, improving patient outcomes while reducing unnecessary side effects.

Read also - Pixel Photonics funding news – Munster-based DeepTech Startup Pixel Photonics Secures €1 Million in Funding

Noora Hujala, CEO and co-founder of Solid IO said, "Every cancer patient deserves a treatment plan based on their unique biology, adapting throughout the treatment journey, We are eliminating trial-and-error in cancer immunotherapy by bringing patient-specific tumor models into clinical use – this is the next evolution in precision oncology."

Transforming Clinical Trials & Drug Development

Beyond improving personalized patient care, Solid IO’s platform is a game-changer for clinical trials and pharmaceutical R&D. The technology offers early patient stratification, biomarker validation, and treatment-response modeling, helping pharmaceutical companies reduce trial timelines, optimize patient selection, and accelerate the development of new immuno-oncology drugs.

Alexandra Gylfe, Partner at Nordic Science Investments said, "Organoids and organ-on-a-chip technology are transforming drug testing. Solid IO provides patient-specific insights in immuno-oncology, and we’re very proud to back this team, whose expertise is truly unique,".

Sandra Golbreich, Partner at BSV Ventures, added: "Despite all the advances in medicine, for too long we’ve relied on educated guesses in cancer treatment. It’s time to move on from uncertainty to real data, and from data to life-saving precision. Solid IO brings a new level of conscious, careful rigour to personalizing treatment for patients unlike any solution we’ve seen. This has a real world impact on people’s lives. We’re glad to partner with NSI on backing such a cutting-edge team.”

About SolidIO

Solid IO operates at the crossroads of medtech, biotech, and deep tech – advancing organ-on-chip technology for precision oncology and immunotherapy. By replicating patient-specific tumor environments, they provide real-time insights that optimize treatment decisions, refine clinical trial design, and accelerate drug development. With a mission to end the guesswork in cancer care, Solid IO is redefining the future of immuno-oncology and precision medicine.